Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre

BACKGROUND: Regorafenib is a multi-kinase inhibitor approved as third line treatment for metastatic GIST. Dose limiting toxicities are frequently seen and many patients require dose reductions. This study aimed to evaluate regorafenib toxicities and their management in a real-world GIST population....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Sarcoma Res
Hauptverfasser: Chamberlain, Florence, Farag, Sheima, Williams-Sharkey, Constance, Collingwood, Cecilia, Chen, Lucia, Mansukhani, Sonia, Engelmann, Bodil, Al-Muderis, Omar, Chauhan, Dharmisha, Thway, Khin, Fisher, Cyril, Jones, Robin L., Gennatas, Spyridon, Benson, Charlotte
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2020
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6942401/
https://ncbi.nlm.nih.gov/pubmed/31911828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-019-0123-4
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge